Panacea Biotec Posts ₹7.16 Cr Net Loss, Faces Going Concern Uncertainty

Panacea Biotec Limited reported a consolidated net loss of ₹7.16 crore for the fiscal year ended March 31, 2026, alongside a significant warning from its auditor and management regarding its ability to continue as a going concern.

Reader Takeaway: Net loss and going concern warning are key pressures; profitable formulations and vaccine pipeline offer hope.

What just happened

Panacea Biotec Limited announced its audited financial results for the year ended March 31, 2026. The company posted a consolidated total income from operations of ₹639.77 crore. However, it registered a consolidated net loss after tax of ₹7.16 crore. The basic and diluted Earnings Per Share (EPS) stood at ₹-0.88.

Why this matters

The most critical aspect for investors is the 'going concern' note. Both the company's auditor and management have highlighted a material uncertainty about Panacea Biotec's ability to continue as a going concern. This is primarily due to negative standalone retained earnings of ₹217.82 crore. The company's board also decided to pass over the dividend for FY 2025-26.

The backstory

Panacea Biotec operates in two main segments: vaccines and formulations. The company's standalone retained earnings have turned negative, signaling accumulated losses over time. This situation necessitates careful management attention and strategic planning to ensure financial stability.

What changes now

Management is relying on long-term vaccine orders, past brand sale proceeds, and working capital measures to support its going concern basis. The company has also appointed Mr. Rajinder Singh Manku as a non-executive independent director, effective July 1, 2026.

Risks to watch

The primary risk is the going concern uncertainty stemming from negative standalone retained earnings. Additionally, the vaccines segment reported a loss before tax of ₹26.84 crore at the EBIT level, impacting overall profitability.

Peer comparison

[No reliable peer comparison data was provided in the filing for this specific event.]

Context metrics (time-bound)

• Consolidated Revenue (FY26): ₹639.77 crore
• Consolidated Net Loss (FY26): ₹7.16 crore
• Vaccines Segment Loss Before Tax (FY26): ₹26.84 crore
• Formulations Segment Profit Before Tax (FY26): ₹19.47 crore
• Standalone Retained Earnings: ₹-217.82 crore

What to track next

Investors should closely monitor the progress of the DengiAll® vaccine, with Phase-III enrollment completed and market entry expected by 2027. The company's ability to improve its standalone financial health and manage its cash flow will be crucial.